Semaglutide benefits besides weight loss include lower cardiovascular and kidney risk, better blood sugar, and improved heart failure symptoms.
Semaglutide benefits besides weight loss include a lower risk of heart attack, stroke, and cardiovascular death, slower progression of chronic kidney disease, better blood sugar control, and improved symptoms in one common form of heart failure. Large randomized trials have also linked the drug to modest improvements in blood pressure, liver fat, knee arthritis pain, and inflammation. Semaglutide is a prescription GLP-1 receptor agonist, and these effects do not replace medical care, so treatment decisions belong with a healthcare professional.
Cardiovascular protection is the best-documented extra benefit
The SELECT trial followed 17,604 adults with overweight or obesity and existing heart disease but no diabetes. People taking semaglutide 2.4 mg had about a 20% lower risk of major adverse cardiovascular events, meaning heart attack, stroke, or death from cardiovascular causes, than those on placebo over roughly three years.
That result led the FDA to approve Wegovy (semaglutide 2.4 mg) in 2024 for reducing cardiovascular risk in adults with established heart disease and excess weight. Semaglutide lowers major cardiovascular events by about 20% in that population, and the benefit does not depend on how many pounds a person loses.
Several mechanisms likely contribute:
- Reduced systemic inflammation, including lower C-reactive protein.
- Small but consistent drops in systolic blood pressure.
- Improved endothelial function and plaque stability.
- Better blood sugar and lipid control.
Kidney protection and heart failure symptoms
The FLOW trial enrolled 3,533 people with type 2 diabetes and chronic kidney disease. Semaglutide 1 mg reduced the risk of kidney disease progression, kidney failure, or death from kidney or cardiovascular causes by 24% compared with placebo.
Based on FLOW, the FDA approved Ozempic in January 2025 to reduce the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease. Semaglutide was the first GLP-1 medication approved for that purpose.
In both trials, the organ-protection benefits appeared on top of standard care, including blood pressure and glucose medications.
In the STEP-HFpEF program, people with obesity-related heart failure with preserved ejection fraction (HFpEF) who took semaglutide 2.4 mg reported meaningful improvements in heart failure symptoms, physical function, and exercise capacity. Semaglutide improves symptoms and physical limitations in obesity-related HFpEF, although it is not FDA-approved for that specific use.
Metabolic, liver, and inflammatory effects
Semaglutide lowers A1c by roughly 1 to 1.5 percentage points in people with type 2 diabetes, which is why Ozempic and Rybelsus are approved for blood sugar control. Systolic blood pressure typically falls 3 to 5 mmHg, and triglycerides and LDL cholesterol improve modestly.
In metabolic dysfunction-associated steatohepatitis (MASH), an earlier semaglutide trial improved liver inflammation scores but did not clearly improve fibrosis. No GLP-1 medication is FDA-approved for MASH, and liver benefits should not be assumed from weight loss alone.
Many people also notice less mental chatter around food and fewer cravings. That reward-pathway effect is being studied in alcohol use disorder and other compulsive behaviors, but the evidence is still early and mostly observational.
Which other health areas have real evidence?
Evidence strength varies a lot by condition. The table below summarizes where semaglutide stands beyond weight loss.
| Health area | What research suggests | Strength of evidence |
|---|---|---|
| Cardiovascular events | About a 20% lower risk of heart attack, stroke, or cardiovascular death (SELECT) | Strong; FDA-approved |
| Chronic kidney disease | 24% lower risk of progression or kidney failure (FLOW) | Strong; FDA-approved |
| Obesity-related HFpEF | Better symptoms, function, and exercise capacity (STEP-HFpEF) | Good; not approved |
| MASH and fatty liver | Lower liver enzymes and liver fat; fibrosis data mixed | Moderate; not approved |
| Knee osteoarthritis | Greater pain reduction than placebo (STEP 9) | Moderate; not approved |
| Obstructive sleep apnea | Some improvement; less data than tirzepatide | Limited |
| PCOS | Better menstrual regularity and metabolic markers | Limited |
| Alzheimer's disease | Large prevention trials still running; no proven benefit | Unproven |
How semaglutide compares with tirzepatide outside weight loss
Tirzepatide (Mounjaro, Zepbound) activates both GIP and GLP-1 receptors, which generally produces greater average weight loss than semaglutide. The non-weight picture is more balanced, and the two drugs have not been compared head-to-head for most of these endpoints.
| Outcome | Semaglutide | Tirzepatide |
|---|---|---|
| Cardiovascular events | Proven reduction of about 20% (SELECT) | Cardiovascular outcome results pending |
| Kidney outcomes | Proven in FLOW | Promising post hoc data |
| Obstructive sleep apnea | Limited trial data | FDA-approved in 2024 |
| Blood sugar control | 1 to 1.5 point A1c drop | Slightly larger average A1c drop |
Anyone reading semaglutide vs tirzepatide weight loss research should keep in mind that weight results and organ-protection results come from different trials in different populations, so the numbers are not directly interchangeable.
Practical points before you count on these benefits
Most organ-protection trials used doses that take months to reach. The starting dose of semaglutide for weight loss is 0.25 mg once weekly, and it is raised slowly to limit nausea, vomiting, and constipation. It helps to understand why increase dose of semaglutide for weight loss is usually a slow process, because the ramp-up limits side effects.
Formulation matters as well. Oral semaglutide weight loss results come from Rybelsus, a daily tablet approved for type 2 diabetes; the SOUL trial found a 14% reduction in major cardiovascular events with the 14 mg oral dose in adults with type 2 diabetes and heart disease or high risk.
Compounded products are a separate category. Online semaglutide with b12 for weight loss reviews often describe mixtures made by compounding pharmacies, which are not FDA-approved and were not studied in the trials described above.
Common side effects are nausea, vomiting, diarrhea, and constipation. Rare but serious risks include pancreatitis, gallbladder disease, and gastroparesis, and semaglutide is not recommended during pregnancy. Talk with a healthcare professional before starting or changing treatment, and do not use these findings to self-treat heart, kidney, or liver disease.
Frequently Asked Questions
Does semaglutide help your heart even if you do not lose much weight?
In the SELECT trial, the cardiovascular benefit appeared largely independent of the amount of weight lost, with about a 20% reduction in heart attack, stroke, and cardiovascular death. That is why semaglutide 2.4 mg is FDA-approved for cardiovascular risk reduction in adults who have existing heart disease plus overweight or obesity.
Is semaglutide approved for anything other than weight loss and diabetes?
Yes. Wegovy is approved to reduce cardiovascular risk in adults with established heart disease and excess weight, and Ozempic is approved to reduce the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease. Uses such as MASH, knee osteoarthritis, and Alzheimer's prevention are still experimental.
Does oral semaglutide have the same non-weight benefits as the injection?
Oral semaglutide (Rybelsus) is approved for type 2 diabetes, and the SOUL trial found a 14% reduction in major cardiovascular events with the 14 mg dose in adults with type 2 diabetes and heart disease or high risk. Kidney and heart failure data are strongest for the injectable forms at 1 mg and 2.4 mg.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.